Research Topics
| Michael ThaseSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacyMichael E Thase
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Int Clin Psychopharmacol 28:113-20. 2013..Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity...- Social skills training for depression and comparative efficacy research: a 30-year retrospectiveMichael E Thase
Perelman School of Medicine, University of Pennsylvania, 3535 Market St, Suite 670, Philadelphia, PA 19104, USA
Behav Modif 36:545-57. 2012.... - The role of monoamine oxidase inhibitors in depression treatment guidelinesMichael E Thase
Department of Psychiatry, Perelman School of Medicine of University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, Philadelphia and Pittsburgh, USA
J Clin Psychiatry 73:10-6. 2012..The availability of a safer and more tolerable formulation gives clinicians another option in their armamentarium for treating depression... - Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depressionMichael E Thase
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Depress Anxiety 29:574-86. 2012.... - Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptomsMichael E Thase
University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
Int J Psychiatry Clin Pract 16:121-31. 2012..placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder... 
Are SNRIs more effective than SSRIs? A review of the current state of the controversyMichael E Thase
University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Psychopharmacol Bull 41:58-85. 2008..Nevertheless, differences in tolerability and cost also must be considered when choosing therapies...- Do antidepressants really work? A clinicians' guide to evaluating the evidenceMichael E Thase
University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
Curr Psychiatry Rep 10:487-94. 2008.... - A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertensionMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 28:302-7. 2008..28 vs -0.64 beats/min; Delta = 2.92, P = 0.004). Although only minor effects on blood pressure were observed in this trial, an infrequent association of bupropion therapy and treatment-emergent hypertension cannot be ruled out... - Pharmacotherapy of mood disordersMichael E Thase
University of Pennsylvania School of Medicine and Veterans Administration Medical Center, Philadelphia, Pennsylvania 19104, USA
Annu Rev Clin Psychol 4:53-91. 2008.... - STEP-BD and bipolar depression: what have we learned?Michael E Thase
University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
Curr Psychiatry Rep 9:497-503. 2007..The STEP-BD results highlight the challenge of treating bipolar depression to remission, illustrate the value of adjunctive psychotherapies, and point to new directions for research... - Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studiesMichael E Thase
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 28:13-20. 2008..8% vs 35.1%) and Study 2 (41.2% vs 29.8%). Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8)... - Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 27:672-6. 2007.... - Recognition and diagnosis of atypical depressionMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19380, USA
J Clin Psychiatry 68:11-6. 2007..Although introduction of safer MAOIs has fostered renewed interest in atypical depression, the validity and importance of the DSM-IV definition of atypical depression for the nosology of affective illness remains an open question... - Selecting appropriate treatments for maintenance therapy for bipolar disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
J Clin Psychiatry 69:28-35. 2008..Additionally, several forms of psychotherapy specifically tailored to the needs of people with bipolar disorder should be considered as an adjunct to medication... 
Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studiesMichael E Thase
Departments of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Prim Care Companion J Clin Psychiatry 10:440-7. 2008..Patients with major depressive disorder (MDD) who fail to achieve complete remission with antidepressant therapy may benefit from augmentation therapy with an atypical antipsychotic...- Antidepressant combinations: widely used, but far from empirically validatedMichael E Thase
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia 19104, USA
Can J Psychiatry 56:317-23. 2011.... - Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture modelMichael E Thase
University of Pennsylvania School of Medicine, and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA USA
Br J Psychiatry 199:501-7. 2011..There is controversy about the implications of relatively small average drug-placebo differences observed in randomised controlled trials of antidepressant medications... - The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?Michael E Thase
Philadelphia Veterans Affairs Medical Center, Perelman School of Medicine of the University of Pennsylvania, University of Pittsburgh Medical Center, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
Curr Psychiatry Rep 13:476-82. 2011..Nevertheless, it is also concluded that the modest benefits of antidepressants in grouped datasets obscure large, specific, and very meaningful therapeutic effects for 10% to 20% of those treated with antidepressants... - Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT studyMichael E Thase
School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
J Psychiatr Res 45:412-20. 2011..034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy... - Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depressionMichael E Thase
University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
Int Clin Psychopharmacol 25:189-98. 2010..In conclusion, the findings indicate that mirtazapine may be a more rapidly effective antidepressant than SSRIs... - Atypical depression: useful concept, but it's time to revise the DSM-IV criteriaMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 15213 2593, USA
Neuropsychopharmacology 34:2633-41. 2009..Research examining the validity of a subform of atypical depression characterized by trait-like interpersonal sensitivity and a chronic, early-onset course may further enhance the clinical utility of the DSM-V classification... - An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
CNS Spectr 14:144-54. 2009..To assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) in outpatients with major depressive disorder... - Update on partial response in depressionMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and Pittsburgh Medical Center, Philadelphia and Pittsburgh, USA
J Clin Psychiatry 70:4-9. 2009..Although studies on predictive factors have not yielded definitive results, clinicians in practice often select adjunctive agents that target patients' persistent symptoms... - Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?Alexandre Y Dombrovski
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Depress Anxiety 25:1060-6. 2008..We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression... - Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BDJoseph F Goldberg
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
J Clin Psychiatry 70:155-62. 2009..Many patients with bipolar disorder receive multi-drug treatment regimens, but the distinguishing profiles of patients who receive complex pharmacologies have not been established... - Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
J Clin Psychiatry 63:434-41. 2002..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction... - Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
Am J Psychiatry 164:739-52. 2007..Cognitive therapy was compared with medication augmentation and switch strategies... - The state of knowledge of chronic depressionAlan J Gelenberg
Department of Psychiatry, Arizona Health Sciences Center, Tucson, AZ, USA
J Clin Psychiatry 67:179-84. 2006 - Pharmacotherapy of bipolar depression: an updateMichael E Thase
University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213 2593, USA
Curr Psychiatry Rep 8:478-88. 2006..Antidepressants--particularly selective serotonin reuptake inhibitors and bupropion--are indicated when mood stabilizers are ineffective and for "breakthrough" depressions... - The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BDChristopher D Schneck
Department of Psychiatry, University of Colorado Health Sciences Center, Denver, CO 80220, USA
Am J Psychiatry 165:370-7; quiz 410. 2008..In a naturalistic follow-up of adult bipolar patients, the authors examined the contributions of demographic, phenomenological, and clinical variables, including antidepressant use, to prospectively observed mood episode frequency... - An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depressionMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
J Clin Psychiatry 70:387-96. 2009..To evaluate the efficacy of olanzapine/fluoxetine combination (OFC) versus olanzapine or fluoxetine monotherapy across all clinical trials of treatment-resistant depression sponsored by Eli Lilly and Company... - Medication augmentation after the failure of SSRIs for depressionMadhukar H Trivedi
Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
N Engl J Med 354:1243-52. 2006..Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach... - Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorderEllen Frank
Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
Arch Gen Psychiatry 59:905-11. 2002..We hypothesized that lifetime panic spectrum features would be associated with higher levels of suicidal ideation and a poorer response to acute treatment of the index mood episode in this patient population... - Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
Control Clin Trials 25:119-42. 2004..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments... - Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg
Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
Biol Psychiatry 54:806-17. 2003..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD... - Optimizing treatment outcomes for patients with depression and generalized anxiety disorderMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 2593, USA
Psychopharmacol Bull 36:93-102. 2002.... - Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP TrialJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
Arch Gen Psychiatry 66:1178-88. 2009..Previous studies have found that few chronically depressed patients remit with antidepressant medications alone... - Acceptability of second-step treatments to depressed outpatients: a STAR*D reportStephen R Wisniewski
Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 164:753-60. 2007..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches... - Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
J Clin Psychiatry 68:1014-23. 2007..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression... - What predicts attrition in second step medication treatments for depression?: a STAR*D ReportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
Int J Neuropsychopharmacol 12:459-73. 2009..Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes... - Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatmentJames H Kocsis
Department of Psychiatry, Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA
J Affect Disord 110:55-61. 2008..These results and the consistency of similar results over time point to the dire need for patient and provider education regarding the signs and symptoms of depression and its treatment... - Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd
Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
Am J Psychiatry 161:1864-71. 2004..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder... - Income and attrition in the treatment of depression: a STAR*D reportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9086, USA
Depress Anxiety 26:622-33. 2009..This report assessed whether attrition rates and predictors of attrition differed among depressed outpatients with different income levels... - Differential effects of treatments for chronic depression: a latent growth model reanalysisNiklaus Stulz
Department of Psychiatry, University of Pennsylvania Philadelphia, PA 19104, USA
J Consult Clin Psychol 78:409-19. 2010.... - Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD studyRoy H Perlis
Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 71:296-303. 2010..Poor medication adherence is common among bipolar patients... - New approaches to managing difficult-to-treat depressionsMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
J Clin Psychiatry 64:3-4. 2003..Challenging subtypes of illness, including psychotic and bipolar subtypes of depression, are not necessarily inherently refractory but must be met with modified treatment approaches... - Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
Am J Psychiatry 163:1905-17. 2006..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Focus on bipolar disorder treatmentCharles L Bowden
Department of Psychiatry, University of Texas Health Science Center at San Antonio, TX, USA
J Clin Psychiatry 66:1598-609. 2005 - Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)Michael E Thase
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
J Clin Psychopharmacol 26:600-9. 2006..This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I)... - Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorderEllen Frank
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Arch Gen Psychiatry 62:996-1004. 2005..Recent investigations have demonstrated benefits from the addition of psychoeducation or psychotherapy to pharmacotherapy in this population... - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
N Engl J Med 354:1231-42. 2006..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another... - Managing depressive and anxiety disorders with escitalopramMichael E Thase
University of Pittsburgh Medical Centre, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
Expert Opin Pharmacother 7:429-40. 2006..Pharmacoeconomic models suggest that the greater drug acquisition cost of this patent-protected compound may be offset by greater efficacy (relative to generic citalopram) and tolerability (compared with extended release venlafaxine)... - Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension studyMichael E Thase
Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
CNS Spectr 11:93-102. 2006..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms... - Effect of age at onset on the course of major depressive disorderSidney Zisook
Department of Psychiatry, University of California, San Diego, CA 92093, USA
Am J Psychiatry 164:1539-46. 2007..This report assesses whether age at onset defines a specific subgroup of major depressive disorder in 4,041 participants who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study... - Bipolar depression: issues in diagnosis and treatmentMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Harv Rev Psychiatry 13:257-71. 2005..The optimal duration of maintenance antidepressant therapy has not been established empirically and, until better evidence-based guidelines are established, should be determined on a case-by-case basis... - Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactionsMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
J Womens Health (Larchmt) 14:609-16. 2005..To investigate whether differences in antidepressant efficacy are moderated by an interaction of age and gender... - Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D studySidney Zisook
Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
J Affect Disord 117:63-73. 2009..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI... - Augmentation strategies for depression: history and conceptsMichael E Thase
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
CNS Spectr 12:3-5. 2007 - Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategiesMichael E Thase
University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA 15213 2593, USA
J Clin Psychopharmacol 26:250-8. 2006.... - Citalopram treatment of paroxetine-intolerant depressed patientsMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
Depress Anxiety 16:128-33. 2002.... - Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment... - What role do atypical antipsychotic drugs have in treatment-resistant depression?Michael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
J Clin Psychiatry 63:95-103. 2002..Although more studies will be required to confirm and extend these findings, the results suggest that there may be a clinical benefit to combining atypical antipsychotics with SSRIs in nonpsychotic TRD... - A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderMichael E Thase
Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Clin Psychiatry 68:224-36. 2007..Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD)... - Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
J Clin Psychiatry 63:493-500. 2002..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances... - Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 30:405-16. 2005..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings... - A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerabilityMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute, Pittsburgh, PA, USA
J Clin Psychopharmacol 26:482-8. 2006..In conclusion, in this patient population (ie, relatively young, sexually active outpatients), bupropion XL was at least as effective as venlafaxine XR and had a significantly more favorable sexual side effect profile... - Stability of symptoms across major depressive episodes in bipolar disorderRoy H Perlis
Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Bipolar Disord 11:867-75. 2009..These studies make the implicit assumption of stability of symptoms across episodes in mood disorders, which has rarely been investigated... - Slower treatment response in bipolar depression predicted by lower pretreatment thyroid functionDaniel P Cole
Department of Psychiatry, University of Pittsburgh School of Medicine, USA
Am J Psychiatry 159:116-21. 2002..It remains to be seen whether pharmacological enhancement of thyroid function will facilitate recovery from bipolar depression... - Management of patients with treatment-resistant depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
J Clin Psychiatry 69:e8. 2008.... - A descriptive analysis of minor depressionMark Hyman Rapaport
Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
Am J Psychiatry 159:637-43. 2002..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder... - Does recovery from substance use disorder matter in patients with bipolar disorder?Roger D Weiss
Department of Psychiatry, Harvard Medical School, Boston, USA
J Clin Psychiatry 66:730-5; quiz 808-9. 2005..To examine the potential impact of recovery from substance use disorder (SUD) on the course of bipolar disorder among patients diagnosed with both bipolar and substance use disorders according to DSM-IV criteria... - Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combinationJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, N Y, USA
J Clin Psychiatry 70:354-61. 2009..We hypothesized that patient preference at baseline would interact with treatment group to differentially affect treatment outcome... - Evaluating antidepressant therapies: remission as the optimal outcomeMichael E Thase
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
J Clin Psychiatry 64:18-25. 2003..e., quantitative and pooled) suggest that both psychotherapy-pharmacotherapy combinations and use of antidepressants that enhance serotonergic and noradrenergic neurotransmission increase the likelihood of remission... - Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapyPaola Rucci
Department of Psychiatry, Western Psychiatric Institite and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
Am J Psychiatry 159:1160-4. 2002..CONCLUSIONS: A treatment program in a maximally supportive clinical environment can significantly reduce suicidal behavior in high-risk patients with bipolar I disorder... - First-line pharmacotherapies for depression - what is the best choice?Aaron M Koenig
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, United States
Pol Arch Med Wewn 119:478-86. 2009.... - Mediators of outcome of psychosocial treatments for cocaine dependencePaul Crits-Christoph
Department of Psychiatry, University of Pennsylvania, PA, USA
J Consult Clin Psychol 71:918-25. 2003..In addition, a measure of beliefs about addiction developed to test mediation of outcome of cognitive therapy was found to correlate moderately with drug use outcomes in both cognitive therapy and individual drug counseling... - An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorderDeborah R Kim
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Womens Health (Larchmt) 20:255-61. 2011..We present the results of an open label pilot study examining treatment with transcranial magnetic stimulation (TMS) in pregnant women with MDD... - Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participantsMark D Fossey
Department of Psychiatry, University of Oklahoma College of Medicine Tulsa, Tulsa, Oklahoma 74135, USA
Am J Addict 15:138-43. 2006..The primary/secondary distinction for SUD is not valid when variations in the age of onset of the non-SUD are linked to course characteristics... - A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorderDavid G S Perahia
Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
J Psychiatr Res 42:22-34. 2008..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller
Brown University, Providence, Rhode Island 02906, USA
Biol Psychiatry 62:1371-9. 2007..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment... - Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BDJoseph F Goldberg
Affective Disorders Program, Silver Hill Hospital, New Canaan, Connecticut, USA
Am J Psychiatry 164:1348-55. 2007..However, few studies have examined the outcomes of patients with co-occurring manic and depressive symptoms who are treated with antidepressants plus mood stabilizing drugs... - Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trialsMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
J Clin Psychiatry 66:974-81. 2005.... - Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Roy H Perlis
Bipolar Clinical and Research Program, Massachusetts General Hospital, ACC 812, 15 Parkman Street, Boston, MA 02114, USA
Am J Psychiatry 163:217-24. 2006..The authors looked for the features associated with risk of recurrence... - Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAndrew A Nierenberg
Massachusetts General Hospital Bipolar Clinic and Research Program, Suite 580, 50 Staniford Street, Boston, MA 02114, USA
Am J Psychiatry 163:210-6. 2006..This study represents the first randomized trial of competing options for treatment-resistant bipolar depression and assesses the effectiveness and safety of antidepressant augmentation with lamotrigine, inositol, and risperidone... - Effectiveness of antidepressants: comparative remission ratesMichael E Thase
University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
J Clin Psychiatry 64:3-7. 2003..Given the better tolerability of newer antidepressants relative to tricyclics, both logic and an increasing amount of data support a greater role for multiaction antidepressants... - Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trialDavid J Miklowitz
Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
Am J Psychiatry 164:1340-7. 2007..In a randomized trial, the authors examined the impact of intensive psychosocial treatment plus pharmacotherapy on the functional outcomes of patients with bipolar disorder over the 9 months following a depressive episode... - Suicidal ideation and pharmacotherapy among STEP-BD patientsJoseph F Goldberg
Affective Disorders Program, Silver Hill Hospital, 208 Valley Road, New Canaan, Connecticut 06840, and Department of Psychiatry, University of Colorado School of Medicine, Denver, USA
Psychiatr Serv 56:1534-40. 2005..Little is known about the effects of lithium on suicidal ideation or about the possible antisuicidal effects of divalproex, second-generation antipsychotics, or antidepressants among persons with bipolar disorder... - Effectiveness of adjunctive antidepressant treatment for bipolar depressionGary S Sachs
Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
N Engl J Med 356:1711-22. 2007..Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania... - Faster remission of chronic depression with combined psychotherapy and medication than with each therapy aloneRachel Manber
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
J Consult Clin Psychol 76:459-67. 2008..The authors conclude that combined antidepressant medications and psychotherapy result in faster full remission of chronic forms of major depressive disorder... - Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D reportPatrick J McGrath
Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
Am J Psychiatry 163:1531-41; quiz 1666. 2006.... - Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?Steven D Hollon
Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA
J Clin Psychiatry 66:455-68. 2005..The authors reviewed the literature with respect to the relative efficacy of medications and psychotherapy alone and in combination in the treatment of depression... - The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyRonald N Marcus
Bristol Myers Squibb, Wallingford, CT 06492, USA
J Clin Psychopharmacol 28:156-65. 2008..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT... - Brief report: paroxetine in younger and adult individuals at high risk for suicideMark S Bauer
Department of Psychiatry, Brown University, USA
Psychopharmacol Bull 39:31-7. 2006..In fact, the younger group showed a trend for decreased suicidality (P = .13). Thus, increased suicidality risk with paroxetine exposure does not extend to this other high-risk mood disordered population, even among younger individuals... - Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD ParticipantsS Nassir Ghaemi
Department of Psychiatry at Emory University in Atlanta, Georgia 30322, USA
Psychiatr Serv 57:660-5. 2006..This study assessed patterns of psychopharmacological treatment for bipolar disorder... - Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studiesRichard H Weisler
Department of Psychiatry and Behavioral Science, Duke University Medical Center, University of North Carolina at Chapel Hill, Raleigh, NC 27609, USA
J Clin Psychiatry 69:769-82. 2008.... - Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled studyIhsan M Salloum
Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center and School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
Arch Gen Psychiatry 62:37-45. 2005..Patients with comorbid substance abuse disorders often are excluded from clinical trials. Thus, treatments targeting this high-risk clinical population are lacking... - Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetineMikael Landen
Section of Psychiatry St Göran, Department of Clinical Neuroscience, Karolinska Institutet, SE 112 81, Stockholm, Sweden
J Clin Psychiatry 66:100-6. 2005.... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller
Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
J Clin Psychiatry 68:1246-56. 2007..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression... - The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medicationAlan J Gelenberg
University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
J Clin Psychiatry 65:1114-9. 2004..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo... - A pilot study of brief interpersonal psychotherapy for depression among womenHolly A Swartz
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Psychiatr Serv 55:448-50. 2004..Both groups improved significantly over time, with large effect sizes. However, contrary to expectations, the women who received psychotherapy improved more quickly than those who received sertraline... - Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trialsGeorge I Papakostas
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 68:1907-12. 2007..The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect...
Research Grants
- PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONMichael E Thase; Fiscal Year: 2010....
- PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONMichael Thase; Fiscal Year: 2009....
- PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONMichael Thase; Fiscal Year: 2007....
- Are Cognitive Therapy's Antidepressant Effects Durable?Michael Thase; Fiscal Year: 2007..Dependent variables measure response, relapse, recurrence, remission, and recovery. Blind evaluations and survival analysis are planned. ..
- PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONMichael Thase; Fiscal Year: 2005..Specifically, if C-CT is significantly more effective than PBO at the end of "Phase 1," then FLX must also have therapeutic activity. ..
- PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONMichael Thase; Fiscal Year: 2004..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
- 1/2-Efficacy of Computer-Assisted Cognitive Behavior Therapy for DepressionMichael E Thase; Fiscal Year: 2010..The proposed study will test the therapeutic equivalence and cost-effectiveness of CCBT versus CBT across a 16 week acute phase and a 6 month follow-up. ..